Announced details
AI drug discovery, target identification, drug discovery lead evaluation, drug repositioning, antibody drug discovery, drug discovery research and development, and collaborative drug discovery
DDAIF has been adopted by multiple major pharmaceutical companies and has accumulated a track record of use (number of companies: Not disclosed)
Introduced as companies using DDAIF (FRONTEO’s AI drug discovery platform), or as companies involved in co-creation or strategic business partnerships with FRONTEO.
5 pharmaceutical companies and biotech ventures. The individual companies’ locations, representatives, capital and years of establishment are not stated.
A total of 21 patents obtained in Japan, Europe, the United States and South Korea (individual patent numbers and expiration dates are not disclosed)
FRONTEO headquarters: Minato-ku, Tokyo
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | FRONTEO AI Innovation Forum 2026, Drug Discovery AI Factory（DDAIF）, DDAIF Innovation Bridge, KIBIT |
| Counterparty | SANTEN PHARMACEUTICAL CO.,LTD., Fuji Pharma Co.,Ltd., Meiji Seika Pharma Co., Ltd., 株式会社エヌビィー健康研究所, 丸石製薬株式会社 |
| Counterparty overview | 5 pharmaceutical companies and biotech ventures. The individual companies’ locations, representatives, capital and years of establishment are not stated. |
| Relationship with the Company | Introduced as companies using DDAIF (FRONTEO’s AI drug discovery platform), or as companies involved in co-creation or strategic business partnerships with FRONTEO. |
| Launch date | 23 July 2026 (conference date; actual) |
| Applicable area | AI drug discovery, target identification, drug discovery lead evaluation, drug repositioning, antibody drug discovery, drug discovery research and development, and collaborative drug discovery |
| Registration number and expiry date | A total of 21 patents obtained in Japan, Europe, the United States and South Korea (individual patent numbers and expiration dates are not disclosed) |
| Location | FRONTEO headquarters: Minato-ku, Tokyo |
| Usage history | DDAIF has been adopted by multiple major pharmaceutical companies and has accumulated a track record of use (number of companies: Not disclosed) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To broadly share practical examples and insights from the use of AI in drug discovery research and business, and promote the implementation of AI drug discovery in society.